###### Strengths and limitations of this study

-   This is the first study to document the current real-world patterns of anticoagulation therapy in managing patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) in Southern China.

-   All the patients were with documented AF and received drug-eluting stent implantation.

-   The present study highlights further efforts should be made to improve the adherence to guideline recommendations for oral anticoagulant treatment among patients with ACS and AF.

-   Data were obtained from two large hospitals in Southern China and do not represent the current treatment status in other regions.

Introduction {#s1}
============

Atrial fibrillation (AF) is the most common arrhythmia worldwide.[@R1] It is associated with a fourfold to fivefold increased risk of ischaemic stroke.[@R2] Known or new-onset AF is a common comorbidity in patients with acute coronary syndrome (ACS). It has been reported that 2%--21% of patients with ACS have a history of AF.[@R4] Patients with ACS and AF have a poor prognostic outcome, including a higher risk of stroke.[@R5] Antithrombotic treatment with oral anticoagulants (OACs), such as warfarin or non-vitamin K antagonist oral anticoagulants (NOACs), is a cornerstone in the prevention of ischaemic stroke in patients with AF.[@R8] However, for patients with AF presenting with acute myocardial infarction (AMI) or coronary artery disease, undergoing percutaneous coronary intervention (PCI), it poses a great challenge with regard to the management of antithrombotic therapy.[@R10] These patients need dual antiplatelet therapy (DAPT) to reduce the risk of subsequent myocardial infarction and stent thrombosis, and OACs treatment to prevent the risk of stroke.[@R11]

Although academic guidelines recommend that a combination of OACs and DAPT should be initiated in these patients and then subsequently switched to single antiplatelet agent combined with OACs,[@R1] OACs have been largely underused in real-world clinical practice.[@R14] However, NOACs have not been applied in most reported studies.[@R14] Recently, there has been a significant price drop in NOACs and more evidence concerning the safety of these agents compared with warfarin. These factors may lead to greater use of NOACs instead of warfarin in patients at higher risk of bleeding, including those undergoing concomitant antiplatelet treatment. However, the prevalence of antithrombotic therapy in Chinese patients with ACS and AF has not been explored after the introduction of NOACs. Therefore, the current study was undertaken to examine current real-world patterns of OAC therapy in managing patients with ACS and AF in Southern China undergoing PCI.

Methods {#s2}
=======

Study population {#s2-1}
----------------

This was a retrospective cohort study conducted in the Shunde Hospital, Southern Medical University and the second hospital of Zhaoqing, China, from January 2013 to 31 December 2018.

We reviewed the medical records of patients aged ≥18 years who were hospitalised for ACS and received PCI treatment. ACS was defined as ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) or unstable angina (UA). STEMI was diagnosed based on elevated levels of biomarkers for myocardial necrosis (including troponin T, troponin I or creatine kinase muscle/brain), with ST-segment elevation of 1 mm or more in at least two contiguous ECG leads,[@R20] whereas NSTEMI was defined as ST-segment depression of ≥1 mm. Patients with typical ischaemic symptoms and no elevation in biomarkers for myocardial necrosis, with or without ECG changes were classified as having UA.[@R21] AF was diagnosed using an ECG recording or a Holter monitor. For patients with length of hospital stay ≥7 days, those with AF lasting \<7 days were classified as having paroxysmal AF,[@R1] and were otherwise classified as having persistent/permanent AF. In patients with no prior history of AF and with length of hospital stay \<7 days, those with AF were defined as unclassified. All of the patients received coronary angiography and PCI. We excluded those with rheumatic heart disease or mechanical heart valves, death during hospitalisation or were transferred out within 3 days, or without discharge medication list available.

Risk stratification and anticoagulation treatment {#s2-2}
-------------------------------------------------

Baseline characteristics including age, sex, smoking, history of hypertension, diabetes, dyslipidaemia, chronic kidney disease, previous stroke/transient ischaemic attack (TIA), history of AF and pre-admission use of OAC, ACS type, Killip classification were collected via the hospital medical record. Blood biochemical measurements, such as fasting plasma glucose, high-density lipoprotein cholesterol, total cholesterol and triglyceride levels were measured using an automated biochemical analyser. Estimated glomerular filtration rate was calculated using the modified Modification of Diet in Renal Disease equation adapted for Chinese.[@R22]

We used the CHA~2~DS~2~-VASc score to evaluate the risk of stroke (congestive heart failure, hypertension, age ≥75 years (doubled), diabetes mellitus, history of stroke/TIA (doubled), vascular disease, age 65--75 years and female sex). The risk of bleeding was evaluated using the HAS-BLED score (hypertension, abnormal renal/liver function, history of stroke, history of bleeding, labile internationally normalised ratio, age \>65 years, non-steroidal anti-inflammatory drugs or alcohol abuse).[@R1]Because data concerning the time in therapeutic range for warfarin was not available, we defined the labile internationally normalised ratio as 'none' and 0 points were given to all patients when calculating the HAS-BLED score.

Prescription of warfarin, NOACs, aspirin and clopidogrel was determined from the discharge medication list. In the hospitals participating in the current study, rivaroxaban and dabigatran were the two types of NOAC available. Standard dosages of NOACs were defined as rivaroxaban 20 mg/day or dabigatran 150 mg two times per day for patients with creatinine clearance ≥50 mL/min, and rivaroxaban 15 mg/day or dabigatran 110 mg two times per day for creatinine clearance of 30--49 mL/min.[@R23] Any daily dosages less than this range were defined as reduced dosages.

Statistical analysis {#s2-3}
--------------------

Patients with AF were divided into two groups based on whether they received OAC treatment or not, at discharge. Baseline characteristics, including CHA~2~DS~2~-VASc score, HAS-BLED scores and antiplatelet therapy were examined. Continuous variables are presented as median (IQR) or mean (SD), as appropriate. Categorical variables are expressed as number (percentages). Continuous variables were compared using the Wilcoxon rank-sum test or Student's t-test after testing for normality using the Kolmogorov-Smirnov test. Categorical variables were compared using the χ^2^ or Fisher's exact test, as appropriate.

Multiple logistic regression models were used to examine the association between baseline characteristics and OAC treatment at discharge. Patients without OAC treatment were used as the reference. The variables adjusted in the multi-variable model were as follows: sex, age (≥65 vs\<65 years), diabetes, hypertension, dyslipidaemia, history of stroke, abnormal renal/liver function, non-steroidal anti-inflammatory drugs or alcohol abuse, history of bleeding, smoking status, type of ACS (UA or myocardial infarction), cardiac function (Killip classification III--IV vs I--II), type of AF (paroxysmal or persistent/permanent) and pre-admission use of OAC. We further set the CHA~2~DS~2~-VASc score and HAS-BLED score as independent factors in the model while their individual components (age, sex, cardiac function, diabetes, hypertension, history of stroke, and history of bleeding) were not included to avoid over-adjustment. Adjusted ORs and corresponding 95% CIs are presented. All the statistical analysis was performed using SPSS V.20.0 (SPSS, Chicago, IL, USA). All comparisons are two-sided, with statistical significance defined as p\<0.05.

Patient and public involvement {#s2-4}
------------------------------

Patients and the general public were not involved in the design and conception of this study.

Results {#s3}
=======

Baseline characteristics {#s3-1}
------------------------

We reviewed 3813 electronic medical records of patients aged ≥18 years, who were hospitalised for ACS and received PCI treatment from January 2013 to December 2018. After excluding 121 patients who died or were transferred out during hospitalisation, and 76 patients without a discharge medication list, 4 patients with mechanical heart valves, a total of 3612 patients were included in this study.

All of the patients received coronary angiography and drug-eluting stent implantation, 1393 of them (38.6%) presented with AMI and received emergent PCI treatment, 2219 of them (61.4%) were diagnosed with UA and received PCI during the index hospitalisation after carefully non-invasive examination.

Among all the included patients, 286 (7.9%) were diagnosed with AF; 45 of these (1.2%) had paroxysmal AF, 227 (6.3%) had persistent/permanent AF and 14 (0.4%) with unclassified AF. According to the hospital medical record, 48 patients were with document history of AF and 26 (54.2%) of them were received OAC therapy prior to admission. Compared with those without AF, patients with ACS and AF were older and more likely to be women, with a higher prevalence of hypertension, diabetes and cardiac dysfunction, previous stroke/TIA, and higher mean CHA~2~DS~2~-VASc and HAS-BLED scores (all p\<0.01, [table 1](#T1){ref-type="table"}).

###### 

Baseline characteristics of patients with ACS and AF and patients with ACS and without AF

  ------------------------------------------------------------------------------
                                         With\             Without AF (n=3326)
                                         AF(n=286)         
  -------------------------------------- ----------------- ---------------------
  Age (year)                             68 (58, 76)\*\*   61 (52,74)

  Sex (female (%))                       128 (44.8)\*      1285 (38.6)

  SBP (mm Hg)                            129.3±22.4\*\*    125.4±23.9

  DBP (mm Hg)                            78.5±18.4\*\*     76.2±17.9

  Hypertension (n(%))                    123 (43.0)\*\*    1214 (36.5)

  Fasting plasma glucose (mmol/L)        5.8±3.6\*         5.4±3.2

  Diabetes mellitus (n(%))               65 (22.7)\*       582 (17.5)

  Serum creatinine (μmol/L)              96 (65,124)       92(63,136)

  eGFR (mL/min/1.73 m^2^)                62.2±25.1\*       70.3±26.0

  Current smoker                         66 (23.1)         729 (21.9)

  LDL-C (mmol/L)                         3.2±1.9           3.0±1.8

  HDL-C (mmol/L)                         1.1±0.6           1.0±0.5

  TC (mmol/L)                            5.4±2.2           5.3±2.2

  TG (mmol/L)                            1.9±1.8           1.8±1.6

  Dyslipidaemia(n(%))                    103 (36.0)        1173 (35.3)

  Previous stroke/TIA (n(%))             17 (5.9)\*        68 (2.0)

  Previous CKD                           19 (6.6)\*        75 (2.3)

  Previous AF                            48 (16.8)         --

  AMI (n(%))                             115 (40.2)        1278 (42.5)

  UA (n(%))                              171 (59.8)        2048 (57.5)

  Killip classification III--IV (n(%))   84 (29.4)\*\*     786 (23.6)

  CHA~2~DS~2~-VASc score                 3.5±2.0\*\*       3.1±1.8

  HAS-BLED score                         3.0±1.6\*\*       2.8±1.7

  Length of hospital stay                7.6±2.9\*\*       7.1±2.6
  ------------------------------------------------------------------------------

Continuous variables are presented as median (IQR) or mean (SD). Categorical variables are expressed as number (percentages).

\*P\<0.05 versus 'without AF' group. \*\*P\<0.01 versus 'without AF' group.

ACS, acute coronary syndrome; AF, atrial fibrillation; AMI, acute myocardial infarction; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride; TIA, transient ischaemic attack; UA, unstable angina.

Antithrombotic therapy {#s3-2}
----------------------

The antithrombotic treatment regimens in patients with ACS and AF and patients with ACS without AF are presented in [table 2](#T2){ref-type="table"}. During the hospital stay, the ratio of parenteral anticoagulant treatment was higher in patients with AF compared with those without AF (35.7% vs 21.0%, p\<0.01). The in-hospital use of antiplatelet agents, including aspirin and clopidogrel, were similar in patients with ACS and AF and patients with ACS and without AF (both p\>0.05). Prescription of OACs in patients with AF was low (n=85, 29.7%); 38 of them received warfarin (13.3%) and 47 of them received NOACs (16.4%). In patients with NOACs treatment, 42 of them (89.3%) received reduced dosages.

###### 

Antithrombotic treatment in patients with ACS and AF and patients with ACS and without AF

                                        With AF (n=286)   Without AF (n=3326)
  ------------------------------------- ----------------- ---------------------
  In-hospital                                             
   Aspirin (n(%))                       280 (97.9)        3291 (98.9)
   Clopidogre l(n(%))                   284 (99.3)        3318 (99.8)
   Parenteral anticoagulants \*(n(%))   102 (35.7)\*      698 (21.0)
   OACs (n(%))                          85 (29.7)\*       8 (0.2)
   Warfarin (n(%))                      38 (13.3)\*       3 (0.1)
   NOACs (n(%))                         47 (16.4)\*       5 (0.2)
  At discharge                                            
   Aspirin (n(%))                       281 (98.3)        3289 (98.9)
   Clopidogrel (n(%))                   282 (98.6)        3316 (99.7)
   OACs (n(%))                          62 (21.7)         7 (0.2)
   Warfarin (n(%))                      30 (10.5)         3 (0.1)
   NOACs (n(%))                         32 (11.2)         4 (0.1)

Categorical variables are expressed as number (percentages).

\*P\<0.01 versus 'without AF' group.

ACS, acute coronary syndrome; AF, atrial fibrillation; NOACs, non-vitamin K antagonist oral anticoagulants; OACs, oral anticoagulants.

At hospital discharge, the use of antiplatelet agents was similar as in-hospital usage, and nearly 99% of patients with or without AF received DAPT. However, only 21.7% of patients with AF (n=62) were discharged on OACs, and 10.5% of them received warfarin and 11.2% received NOACs ([table 2](#T2){ref-type="table"}). Similarly, in patients with NOACs treatment, 90.6% of them received reduced dosages.

Determinants of OACs treatment at discharge {#s3-3}
-------------------------------------------

We examined the association between baseline characteristics and OAC treatment at discharge. In all the included patients with AF, only 4.5% were at moderate risk (CHA~2~DS~2~-VASc score 1), and 95.5% were at high risk (CHA~2~DS~2~-VASc score ≥2) of stroke. In terms of bleeding, 31.8% of the patients had a HAS-BLED score ≥3, which was defined as a high risk of bleeding. The baseline characteristics of the patients with AF received OACs or not at discharge are presented in [table 3](#T3){ref-type="table"}. As shown in [table 4](#T4){ref-type="table"}, patients with pre-admission use of OACs, a HAS-BLED score \<3, with persistent/permanent AF were more likely to receive OACs treatment at discharge. However, neither a high risk of stroke nor other clinical characteristics were associated with OACs treatment.

###### 

Characteristics of the patients with AF received OAC or not at discharge

                                                               OAC treatment (n=62)   Non-OAC treatment (n=224)
  ------------------------------------------------------------ ---------------------- ---------------------------
  Age (year)                                                   69 (57, 77)            68 (59, 76)
  Sex (female (%))                                             30 (48.4)              98 (43.8)
  Smoking (n(%))                                               16 (25.8)              50 (22.3)
  Hypertension (n(%))                                          32 (51.6)              91 (40.6)
  Diabetes mellitus (n(%))                                     19 (30.6)              46 (20.5)
  Dyslipidaemia (n(%))                                         20 (32.3)              83 (37.1)
  Abnormal renal (n(%))                                        5 (8.1)                14 (6.3)
  Abnormal liver function (n(%))                               1 (1.6)                4 (1.8)
  Non-steroidal anti-inflammatory drugs/alcohol abuse (n(%))   4 (6.5)                21 (9.4)
  Killip classification III--IV (n(%))                         21 (33.9)              63 (28.1)
  History of stroke (n(%))                                     8 (12.9)\*             9 (4.0)
  History of bleeding (n(%))                                   2 (3.2)                19 (8.5)
  AMI (n(%))                                                   25 (40.3)              90 (40.2)
  CHA~2~DS~2~-VASc score ≥2 (n(%))                             61 (98.4)              212 (94.6)
  HAS-BLED score ≥3 (n(%))                                     12 (19.4)\*\*          79 (35.3)
  Persistent/permanent AF (n(%))                               59 (95.2)\*\*          168 (75)
  Pre-admission use of OAC (n(%))                              19 (30.6)\*\*          7 (3.1)

\*P\<0.05 versus 'non-OAC' group. \*\*P\<0.01 versus 'non-OAC' group.

AF, atrial fibrillation; AMI, acute myocardial infarction; OAC, oral anticoagulant.

###### 

Determinants of oral anticoagulant treatment at discharge

  -------------------------------------------------------------------------------------------------
  Determinants                                                      OR     95% CI         P value
  ----------------------------------------------------------------- ------ -------------- ---------
  Sex (male vs female)                                              0.90   0.44 to 1.84   0.77

  Age (≥65 vs \<65 years)                                           1.38   0.31 to 6.14   0.67

  Smoking (yes vs no)                                               1.07   0.26 to 4.40   0.93

  Diabetes mellitus (yes vs no)                                     1.48   0.80 to 2.74   0.21

  Hypertension (yes vs no)                                          1.35   0.43 to 4.24   0.61

  Dyslipidaemia (yes vs no)                                         0.73   0.21 to 2.54   0.62

  Abnormal renal (yes vs no)\                                       1.25   0.55 to 2.84   0.59
  Abnormal liver function (yes vs no)                                                     

  Non-steroidal anti-inflammatory drugs/alcohol abuse (yes vs no)   1.02   0.23 to 4.52   0.97

  Cardiac function (Killip classification III--IV vs I--II)         1.40   0.65 to 3.02   0.39

  History of stroke (yes vs no)                                     2.76   0.94 to 8.10   0.06

  History of bleeding (yes vs no)                                   0.80   0.23 to 2.78   0.73

  Type of ACS (AMI vs UA)                                           0.95   0.19 to 4.75   0.95

  Type of AF (persistent/permanent vs paroxysmal)                   4.32   1.25 to 14.9   0.02

  CHA~2~DS~2~-VASc score (≥2 vs \<2)                                2.65   0.93 to 7.55   0.07

  HAS-BLED score (\<3 vs ≥3)                                        3.10   1.18 to 8.14   0.02

  Pre-admission use of OAC (yes vs no)                              8.92   2.69 to 29.6   0.0003
  -------------------------------------------------------------------------------------------------

The variables adjusted in the multi-variable model were s follows: sex, age (≥65 vs \<65 years), diabetes, hypertension, history of stroke, history of bleeding, smoking status, type of ACS (UA or MI), cardiac function (Killip classification III--IV vs I--II) and type of AF (paroxysmal or persistent/permanent). Abnormal renal function was defined as chronic dialysis, renal transplant, serum creatinine ≥2.3 mg/dL (200 µmol/L); abnormal liver function was definced as chronic hepatic disease (eg, cirrhosis) or bilirubin \>2×upper limit of normal, in association with aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase \>3×upper limit normal. When CHA~2~DS~2~-VASc score and HAS-BLED score were included as independent factors in the model, the individual components (age, sex, cardiac function, diabetes, hypertension, history of stroke and history of bleeding) were not included to avoid over-adjustment.

ACS, acute coronary syndrome; AF, atrial fibrillation; AMI, acute myocardial infarction;MI, myocardial infarction; UA, unstable angina.

Discussion {#s4}
==========

There are three main findings in this study. First, the overall incidence of AF was 7.9% in patients with ACS and received PCI during hospitalisation. Second, although most patients with AF had a high risk of stroke, less than 30% received OACs treatment at discharge. Third, patients with pre-admission use of OACs, a lower risk of bleeding and persistent/permanent AF were more likely to receive anticoagulation therapy after PCI.

DAPT was recommended in patients with ACS who underwent PCI to reduce the risk of stent thrombosis.[@R21] However, antiplatelet treatments have no clinical benefit in the treatment of AF. For patients with AF who undergo PCI, if the CHA2DS2-VASc score ≥2, initial treatment with DAPT plus OACs (triple therapy) for at least 4 weeks is recommended under the current guidelines.[@R1] However, such a 'triple therapy' strategy poses risks for bleeding and OACs are globally underused in clinical practice.[@R14] The China acute myocardial infarction (CAMI) registry found that from 2013 to 2014, only 5.1% of patients with ACS and AF were treated using warfarin, and 1.7% were treated using both warfarin and DAPT.[@R25] No NOACs were prescribed in patients with ACS and AF in the CAMI study. In the current study, we found that this situation was improved. Approximately 30% of patients with ACS and AF who underwent PCI received anticoagulation therapy at discharge, and half of them were prescribed with NOACs. This improvement may be caused by the accumulation of clinical research data, the availability of consensus guidelines for treatment, increased physician awareness of anticoagulation therapy and a price reduction in NOACs in China. However, it should be noted that OACs were still greatly underused.

Compared with warfarin, NOACs are more convenient to use, including advantages such as fixed dose regimens, no requirement for frequent blood monitoring, no food and drug restrictions and less risk of bleeding.[@R26] In the current study, we found that there was a substantially increased use of NOACs in Chinese patients during the past few years. This is consistent with data from the Danish nation-wide administrative registries, which found that by 2016, the use of NOACs in any combination with antiplatelets was exceeding that of warfarin in combination with antiplatelets.[@R28] However, in the current cohort, most patients (approximately 90%) received a reduced dosage of NOACs, such as rivaroxaban 10 mg/day. This may be driven primarily by the concern for increased risk of bleeding. It has been reported that in patients with AF and AMI and/or PCI, when in combination with DAPT, low-dose NOACs plus DAPT was associated with a lower rate of bleeding than a vitamin K antagonist plus DAPT.[@R29]

In contrast with previous studies which showed that the use of OACs in patients with ACS and AF was influenced by neither stroke risk nor bleeding risk,[@R18] our study found that patients with a HAS-BLED score \<3 were more likely to receive OACs treatment at discharge. Furthermore, the number of patients treated with OACs at discharge (21.7%) was significantly decreased than that during hospitalisation (29.7%). These results suggest that physicians are still hesitant to prescribe 'triple therapy' because of concerns about the risk of bleeding. Both the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA)/European Society of Cardiology (ESC) guidelines for the management of patients with AF have proposed a clear algorithm for the management of these patients.[@R1] The most recently AHA/ACC/HRS guideline recommended that in patients with ACS and AF at increased risk of stroke, double therapy with P2Y12 inhibitors (clopidogrel) and low-dose rivaroxaban 15 mg daily or dabigatran 150 mg two times per day is reasonable to reduce the risk of bleeding, as compared with triple therapy.[@R1] The EHRA/ESC guideline also proposed that dual therapy with OACs plus clopidogrel may be considered in patients with excessive bleeding risk and low thrombotic risk.[@R12] However, providing optimal treatment is still a great challenge in real-world practice. In this study, we found that patients with ACS after PCI and AF were almost all treated with DAPT (nearly 99% of patients). However, OACs is greatly underused. These results pointed out a very 'awkward' situation, clinicians are concern about the risk of bleeding as well as stent thrombosis, so they choose to select DAPT but not double therapy with one P2Y12 inhibitor and OACs. These results showed that there are great gaps between real clinical practice and recommendations from the academic guidelines. Further efforts should be made to improve the adherence to guideline recommendations for OACs treatment among patients with ACS and AF.

The current study further found that patients with paroxysmal AF were less likely to receive OACs than those with persistent/permanent AF. This was not a surprise. The AHA/ACC/HRS guideline for the management of AF recommended that for patients with paroxysmal AF, the need for anticoagulant therapy should be determined based on the risk of stroke, same with persistent AF.[@R1] However, studies have shown that the risk of stroke in patients with paroxysmal AF is lower than that those with persistent/permanent AF.[@R31] The benefit of anticoagulation in new-onset AF, occurring in the setting of an acute attack with ACS, acute pulmonary disease or sepsis, is associated with a higher risk of bleeding, but not with a reduced risk of ischaemic stroke.[@R33] Therefore, for paroxysmal AF that occurs in the case of ACS, there is still much doubt about whether these patients need long-term anticoagulant therapy. Recently, a study showed that in patients with paroxysmal AF, a greater burden of AF is associated with a higher risk of ischaemic stroke.[@R34] Therefore, follow-up studies should be conducted to observe the re-occurrence of AF in the future.

There are some limitations in the current study. First, we did not evaluate the link between anticoagulant therapy and adverse events during hospitalisation and after discharge. Second, patient status was distinguished as paroxysmal AF or persistent/permanent AF based on medical records, so misclassifications cannot be totally avoided. Third, as a retrospective study, data were obtained from two large hospitals in Guangdong Province, China, and do not represent the current treatment status of other regions. Finally, we also found that some patients without AF were prescribed with OACs; however, the indications were unrecorded.

Conclusion {#s5}
==========

This study found that nearly 8% of patients who underwent PCI during ACS hospitalisation had AF. Although these patients were at an increased risk of stroke, anticoagulant therapy was greatly underused. Patients with paroxysmal AF and an increased risk of bleeding were less likely to receive anticoagulant treatment. The promotion of NOACs use can increase the treatment of anticoagulation in these patients.
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